Table 4.
Factors influencing overall survival (OS) after recurrence or progression in a portion of our cohort (n = 787).
| Variable | No. | 2-Year OS rate after recurrence, % | Univariate |
Multivariate |
||
|---|---|---|---|---|---|---|
| HR (95%CI) | P-valuea | HR (95%CI) | P-valuea | |||
| Age | 0.046 | 0.15 | ||||
| <60 years | 384 | 46.8 | 1 | 1 | ||
| ⩾60 years | 403 | 39.4 | 1.20 (1.00–1.44) | 1.21 (0.94–1.56) | ||
| CA-125 levelsb | <0.0001 | <0.0001 | ||||
| ⩽35 IU/L | 114 | 64.0 | 1 | 1 | ||
| >35 IU/L | 346 | 41.8 | 1.97 (1.43–2.72) | 2.02 (1.44–2.84) | ||
| Thrombocytosisb | <0.0001 | 0.002 | ||||
| No | 382 | 49.3 | 1 | 1 | ||
| 67 | 28.7 | 2.00 (1.47–2.71) | 1.67 (1.21–2.30) | |||
| VTE | 0.05 | 0.97 | ||||
| No | 625 | 45.3 | 1 | 1 | ||
| 162 | 35.2 | 1.24 (1.00–1.54) | 1.01 (0.74–1.37) | |||
| Stage-specific histologic subtype | <0.0001 | |||||
| Advanced SOC | 642 | 46.3 | 1 | 1 | ||
| Advanced OCCC | 80 | 17.0 | 2.24 (1.70–.94) | 2.68 (1.90–3.79) | <0.0001 | |
| Early-stage SOC | 32 | 61.3 | 0.59 (0.33–1.05) | 0.84 (0.44–1.60) | 0.60 | |
| Early-stage OCCC | 33 | 29.5 | 1.20 (0.77–1.89) | 2.12 (1.30–3.44) | 0.002 | |
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous thromboembolism; SOC, serous ovarian carcinoma; OCCC, ovarian clear cell carcinoma.
a
The log-rank test was used for univariate analysis and Cox proportional hazards regression modelling was used for multivariate analysis.
b
CA-125 and platelet counts were measured at the time of first recurrence or progression of disease.